More than 7,000 confirmed clinical cases of Candida auris, a drug-resistant fungus that thrives in hospitals and long-term care facilities, have been recorded across the United States since national tracking began. The organism kills a significant share of patients who develop bloodstream infections, and laboratory testing shows it is increasingly resistant to the limited antifungal drugs available. The acceleration in cases after 2019, compounded by COVID-19 pandemic pressures on infection control, has turned what was once a rare pathogen into a persistent threat inside American healthcare networks.
Post-2019 acceleration and the resistance problem
The CDC has classified Candida auris as an “urgent antimicrobial resistance threat,” a designation reserved for pathogens posing the highest level of danger to public health. That label is not theoretical. A peer-reviewed study published in Emerging Infectious Diseases reported that 8,033 clinical isolates were tested by the Antimicrobial Resistance Laboratory Network during 2022 and 2023. The results showed high rates of fluconazole resistance, along with resistance to amphotericin B and echinocandins, the two remaining drug classes that clinicians rely on when first-line treatments fail.
Echinocandin resistance is especially alarming because these drugs are considered the front-line therapy for invasive Candida auris infections. When echinocandins stop working, treatment options narrow to almost nothing. The 2022–2023 testing data from the AR Lab Network confirmed that resistance to this drug class is no longer an isolated finding but a recurring pattern across clinical samples collected from multiple U.S. regions. In some clusters, isolates showed resistance to more than one antifungal class, raising the specter of pan-resistant strains that are nearly impossible to treat.
The spread did not begin in 2022. A peer-reviewed analysis published in the Annals of Internal Medicine documented clinical case growth and geographic expansion through 2021, with resistance signals emerging during the COVID-19 era. Pandemic-era conditions, including overwhelmed intensive care units, extended patient stays, widespread ventilator use, and strained infection-control staffing, created ideal conditions for a surface-persistent fungus to move between patients and facilities. The CDC’s own communications, archived in its online media library, underscore that the post-2019 acceleration in spread coincided with these systemic stresses and that healthcare facilities remain the primary transmission setting.
How CDC counts cases and why totals shift
The 7,000-case figure draws from the CDC’s national surveillance infrastructure, including the NNDSS Table 1F dataset, which publishes weekly confirmed counts for notifiable diseases including Candida auris. These data are compiled from reports submitted by state and local health departments, then standardized into a national table that can be filtered by week, jurisdiction, and pathogen. Annual totals are also displayed on the agency’s tracking page, which notes that CDC totals can differ from state counts or other surveillance systems due to reporting lags, case-definition differences, and data reconciliation timelines.
A significant methodological change took effect in 2023. According to CDC documentation on the NNDSS reporting system, only confirmed Candida auris clinical cases are now published. Before 2023, both confirmed and probable cases were included in published totals. That shift means current annual counts exclude a category of cases that would have been tallied in earlier years, making direct year-over-year comparisons more complicated than they appear and potentially understating the true burden in jurisdictions that still classify many reports as probable.
This definitional change matters for anyone trying to assess whether the fungus is spreading faster or whether better testing is simply catching more cases. The answer, based on the available evidence, is both. Genomic sequencing performed by the CDC and AR Lab Network across U.S. regions, published in a separate Emerging Infectious Diseases study, revealed regional clustering and multiple clades circulating through healthcare networks. Public genomic data deposited in the NCBI Sequence Read Archive under BioProject PRJNA638416 allows independent researchers to verify these findings. The sequencing data show that specific genetic lineages are establishing themselves in hospital systems, not merely being detected more often because labs are looking harder.
At the same time, expanded screening has clearly contributed to higher case counts. More facilities now perform targeted testing on patients transferred from high-risk settings, such as long-term acute care hospitals and skilled nursing facilities, and more clinical laboratories have adopted molecular methods capable of distinguishing Candida auris from related yeasts. As a result, colonization is being identified in patients who might previously have gone undetected, and those colonized individuals can seed future outbreaks even if they never develop invasive disease themselves.
Gaps in the public record on patient outcomes and facility-level data
The surveillance system tracks where Candida auris turns up, but it does not publicly report what happens to the patients who contract it. Patient-level outcome data, including mortality rates, length of hospital stay, and treatment response, are not available in the NNDSS weekly tables or the AR Lab Network’s published resistance summaries. That gap leaves clinicians, hospital administrators, and patients without a clear, nationally standardized picture of how lethal the fungus is in practice across different facility types and patient populations.
State-by-state discrepancies add another layer of uncertainty. The CDC’s tracking page acknowledges that its totals can differ from numbers reported by individual state health departments. No publicly available reconciliation file explains where those differences originate or how large they are. Some of the divergence likely stems from delays in transmitting case reports to the national system, while other differences may reflect local decisions about which colonization events to count. For hospital infection-control teams trying to benchmark their own facility’s risk, the absence of granular, facility-level data limits the ability to compare performance, identify outliers, or learn from centers that have successfully contained spread.
Facility-level transparency is particularly constrained for long-term care settings, which have been central to many documented outbreaks. While infection-prevention specialists know that ventilator-capable nursing homes and long-term acute care hospitals are high-risk environments, there is no national, publicly accessible map showing which facilities have experienced repeated transmission or which have implemented enhanced control measures. Without that visibility, families choosing care settings and clinicians arranging transfers must often make decisions without a clear view of Candida auris history in the receiving institution.
Researchers and policymakers say more detailed, de-identified outcome data could help answer urgent questions. How often do colonized patients progress to invasive infection? Which antifungal regimens are associated with better survival in the face of emerging resistance? Are certain infection-control bundles-such as dedicated staff cohorts, enhanced environmental cleaning, and active surveillance cultures-consistently linked to lower transmission rates? Robust national data could support evidence-based guidelines and allow resource-limited facilities to prioritize the most effective interventions.
For now, the public record presents a partial view: rising counts, expanding geography, and mounting drug resistance, but only scattered snapshots of what those trends mean at the bedside. As Candida auris continues to entrench itself in U.S. healthcare, closing the information gaps on outcomes and facility performance may be as important as developing new drugs. Without clearer data, the true human cost of this fungus-and the most effective ways to prevent it-will remain frustratingly hard to pin down.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
